©2024 Stanford Medicine
Side Effects of Antipsychotic Medications
Not Recruiting
Trial ID: NCT00363181
Purpose
Medications like olanzapine have been associated with the development of weight gain and
diabetes in some patients. It is not known if the increased risk of developing diabetes is a
direct effect on insulin or simply related to weight gain.
We hope to learn in this study whether or not olanzapine directly slows down insulin
secretion from the pancreas, thereby increasing the risk of developing diabetes.
Official Title
Does Olanzapine Inhibit the Secretory Response to Insulin Resistance?
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
- Participants 30-66 years of age
- Body mass index (BMI) >25 < 35 kg/m2.
- Fasting plasma glucose concentration < 126 mg/dL
- Stable on one of the following psychiatric medication: Olanzapine (Zyprexa®),
Ziprasidone (Geodon®), Aripiprazole (Abilify®), or Risperidone (Risperdal®)
- Stable on psychiatric medication for at least 3 months
Exclusion Criteria:
- Medications that directly affect insulin-mediated glucose disposal
- Intense suicidal impulses/intent
- Alcohol or substance abuse for 3 months.
- Major medical problems, i.e., clinically unstable medical disorder or condition;
cardiovascular, hepatic, renal, gastrointestinal, pulmonary, endocrine or other
systemic disease that would, in the investigator's clinical judgment interfere with
the endocrine measures obtained in this study.
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Lilla Nikolics, Ms
650-493-5000 Ext. 67289